These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
14. [Beneficial effect of bromocriptine in a patient with malignant syndrome and hepatic dysfunctions]. Onaka A; Aibiki M; Shirakawa Y; Chikano S; Yokono S; Ogli K Masui; 1993 Mar; 42(3):431-4. PubMed ID: 8468790 [TBL] [Abstract][Full Text] [Related]
15. Neuroleptic malignant syndrome: successful treatment with dantrolene and bromocriptine. Granato JE; Stern BJ; Ringel A; Karim AH; Krumholz A; Coyle J; Adler S Ann Neurol; 1983 Jul; 14(1):89-90. PubMed ID: 6614876 [TBL] [Abstract][Full Text] [Related]
16. [A cocaine-induced variant of the neuroleptic malignant syndrome. A case study]. Smidt MH; Collumbien EC Tijdschr Psychiatr; 2006; 48(5):399-404. PubMed ID: 16956032 [TBL] [Abstract][Full Text] [Related]
17. [Significance of serum myosin light chain-1 level in neuroleptic malignant syndrome]. Konagaya M; Iida M; Konagaya Y No To Shinkei; 1994 Apr; 46(4):373-8. PubMed ID: 8024837 [TBL] [Abstract][Full Text] [Related]
18. Drug treatment of the neuroleptic malignant syndrome. Sakkas P; Davis JM; Janicak PG; Wang ZY Psychopharmacol Bull; 1991; 27(3):381-4. PubMed ID: 1685592 [TBL] [Abstract][Full Text] [Related]
19. Neuroleptic malignant syndrome without neuroleptics. Ong KC; Chew EL; Ong YY Singapore Med J; 2001 Feb; 42(2):85-8. PubMed ID: 11358199 [TBL] [Abstract][Full Text] [Related]